Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4100 Horizons Drive, Suite 205 COLUMBUS OH 43220 |
Tel: | N/A |
Website: | https://www.navidea.com |
IR: | See website |
Key People | ||
Craig Dais Chief Financial Officer, Principal Accounting Officer |
Business Overview |
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company's business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS). |
Financial Overview |
For the nine months ended 30 September 2023, Navidea Biopharmaceuticals Inc revenues decreased from $65K to $0K. Net loss applicable to common stockholders excluding extraordinary items decreased 61% to $5.3M. Revenues reflect Grant and other revenue decrease from $51K to $0K, Sales revenue decrease from $14K to $0K. Lower net loss reflects Corporate segment loss decrease of 44% to $3.7M, Diagnostics segment loss decrease of 21% to $3M. |
Employees: | 11 as of Mar 17, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1.59M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$10.07M as of Sep 30, 2023 |
Net annual income (TTM): | -$8.81M as of Sep 30, 2023 |
Free cash flow (TTM): | -$9.91M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 100,084,385 as of Nov 10, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |